We have a clinical-stage platform technology to generate best-in-class ADCs which is validated by >$420m in deals across 3 partnerships. Our business model is technology out-licensing.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
No Synaffix pipeline / only technology out-licensing
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):